This article discusses the efficacy of denosumab, an anti-osteoporotic agent, in treating osteoporosis in male patients with ankylosing spondylitis (AS). AS is a risk factor for osteoporosis, but men with AS are less likely to receive treatment compared to women. The study used quantitative computed tomography (qCT) to measure bone density in six male AS patients who were treated with denosumab. The results showed that denosumab increased spinal bone mineral density (BMD) by almost 30% after two doses, and its efficacy persisted for the next two doses. The study highlights the utility of qCT for assessing BMD in men with AS and the need for further research on screening and treatment for osteoporosis in AS patients. [Extracted from the article]